Abstract
Hypertension is now established as a major risk factor for premature cardiovascular morbidity and mortality in people with Type 2 diabetes and all modern treatment guidelines recommend the routine treatment of hypertension in these patients. However, these developments have been relatively recent. Only a decade ago, outside of small studies in patients with nephropathy, there was little evidence with regard to the efficacy and safety of treating elevated blood pressure in people with Type 2 diabetes. Consequently, for many patients, elevated blood pressure remained undetected and untreated. This changed with the publication of the Hypertension in Diabetes Study (HDS) in 1998. This study revealed that hypertension was very common in people with Type 2 diabetes and demonstrated the dramatic benefits of blood pressure lowering in reducing their risk of major macrovascular and microvascular complications. The unequivocal evidence from this study provided a much-needed catalyst for change, propelling blood pressure measurement and its treatment to the forefront of risk management in these patients. Many studies have followed and many questions remain with regard to the preferred anti-hypertensive treatment strategy and optimal treat...Continue Reading
References
Feb 1, 1974·Diabetes·M J GarciaW B Kannel
Mar 1, 1993·Journal of Hypertension
Mar 1, 1993·Journal of Hypertension
Sep 11, 1998·BMJ : British Medical Journal
Sep 11, 1998·BMJ : British Medical Journal
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Apr 9, 2002·Lancet·Lars H LindholmUNKNOWN LIFE Study Group
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Apr 27, 2005·Archives of Internal Medicine·Mahboob RahmanThomas Wiegmann
Jun 29, 2005·Archives of Internal Medicine·Paul K WheltonUNKNOWN ALLHAT Collaborative Research Group
Jun 29, 2005·Archives of Internal Medicine·Fiona TurnbullUNKNOWN Blood Pressure Lowering Treatment Trialists' Collaboration
Sep 13, 2005·Lancet·Björn DahlöfUNKNOWN ASCOT Investigators
Oct 21, 2006·Journal of Hypertension·Alberto ZanchettiOyvind Störset
Jul 12, 2007·The American Journal of Cardiology·UNKNOWN ACCORD Study GroupMark D Sullivan
Sep 4, 2007·Lancet·Anushka PatelB Williams
Feb 8, 2008·The New England Journal of Medicine·Peter GaedeOluf Pedersen
May 3, 2008·Journal of the American College of Cardiology·Bryan Williams
Citations
Jul 6, 2010·Diabetes Technology & Therapeutics·Kenneth A EarleBee Tang
Mar 20, 2010·BMC Public Health·Manuel A Gómez-MarcosLuis García-Ortiz
May 23, 2012·Cardiovascular Diabetology·Boon How ChewMohd Adam Bujang
Aug 14, 2012·International Journal of Hypertension·Siriwat Tiptaradol, Wichai Aekplakorn
Feb 17, 2009·Diabetes/metabolism Research and Reviews
Aug 1, 2010·Current Therapeutic Research, Clinical and Experimental·Wei-Xin LiLin Yang
Jul 30, 2015·PloS One·Ina-Maria RückertChrista Meisinger
Mar 23, 2011·Human Vaccines·Isla OgilvieMireille M Goetghebeur
Oct 9, 2018·Cerebral Cortex·Judith NicolasDenis Pélisson
Jan 1, 2016·Expert Review of Endocrinology & Metabolism·Darshan KhanguraJames R Sowers